Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2022 Jun 27.
Published in final edited form as: Breast Cancer Res Treat. 2022 Jun;193(3):565. doi: 10.1007/s10549-022-06613-4

Correction to: Definitive results of a phase III adjuvant trial comparing six cycles of FEC-100 to four cycles of AC in women with operable node-negative breast cancer: the NSABP B-36 trial (NRG Oncology)

Charles E Geyer Jr 1,2, Hanna Bandos 1,3, Priya Rastogi 1,2,4, Samuel A Jacobs 1, André Robidoux 1,5, Louis Fehrenbacher 1,6, Patrick J Ward 1,7, Jonathan Polikoff 1,8, Adam M Brufsky 1,4, Louise Provencher 1,9, Alexander H G Paterson 1,10, John T Hamm 1,11, Robert L Carolla 1,12, Luis Baez-Diaz 1,13, Thomas B Julian 1,14, Sandra M Swain 1,15, Eleftherios P Mamounas 1,16, Norman Wolmark 1,2
PMCID: PMC9235403  NIHMSID: NIHMS1808379  PMID: 35507135

In the original publication of the article, the word cyclophoshamide in abstract and introduction was published incorrectly. The corrected word should read as cyclophosphamide.

The original article has been corrected.

RESOURCES